Sam Brusco, Associate Editor09.01.22
Viz.ai has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its automated RV/LV ratio algorithm for the Viz PE solution.
The algorithm quickly and accurately measures diameter of the heart’s ventricles to provide the correct ratio of the maximum right ventricle (RV) diameter versus the left ventricle (LV). Integrating the RV/LV algorithm gives the solution an automated assessment of potential right ventricle dilation.
“The Viz.ai automated CT scan clot detection system improves diagnostic acumen and expedites care for patients with acute pulmonary embolism,” Dr. Kenneth Rosenfield, Interventional Cardiologist, Section Head of Vascular Medicine and Intervention at Massachusetts General Hospital told the press. “But the true killer in patients with PE is failure of the right heart. With this clearance, the Viz PE Solution now includes both detection of clot in the lungs and degree of strain on the right heart. This will enable clinicians to quickly triage patients and treat them appropriately, by providing a powerful tool for early detection and risk stratification. This expedited critical decision-making will undoubtedly save lives.”
“With AI-powered enhanced image interpretation that dramatically improves the quality and speed of mobile image viewing—and caregiver communication—Viz PE already helps identify suspected pulmonary embolisms in under two minutes,” said Jayme Strauss, chief clinical officer, Viz.ai. “The addition of the RV/LV algorithm is expected to further aid care teams to quickly make the right clinical decision for their patients, improving outcomes and saving lives.”
The algorithm quickly and accurately measures diameter of the heart’s ventricles to provide the correct ratio of the maximum right ventricle (RV) diameter versus the left ventricle (LV). Integrating the RV/LV algorithm gives the solution an automated assessment of potential right ventricle dilation.
“The Viz.ai automated CT scan clot detection system improves diagnostic acumen and expedites care for patients with acute pulmonary embolism,” Dr. Kenneth Rosenfield, Interventional Cardiologist, Section Head of Vascular Medicine and Intervention at Massachusetts General Hospital told the press. “But the true killer in patients with PE is failure of the right heart. With this clearance, the Viz PE Solution now includes both detection of clot in the lungs and degree of strain on the right heart. This will enable clinicians to quickly triage patients and treat them appropriately, by providing a powerful tool for early detection and risk stratification. This expedited critical decision-making will undoubtedly save lives.”
“With AI-powered enhanced image interpretation that dramatically improves the quality and speed of mobile image viewing—and caregiver communication—Viz PE already helps identify suspected pulmonary embolisms in under two minutes,” said Jayme Strauss, chief clinical officer, Viz.ai. “The addition of the RV/LV algorithm is expected to further aid care teams to quickly make the right clinical decision for their patients, improving outcomes and saving lives.”